A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.

Trial Profile

A Phase I/II Clinical Trial of the Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane) in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Azacitidine
  • Indications Advanced breast cancer; Lymphoma; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 14 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Feb 2015 Planned End Date changed from 1 Nov 2014 to 1 Nov 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top